S. Bruce Benson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Bruce Benson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Gaither
Department of Pharmaceutical Care & Health Systems (PCHS), College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
3 shared publications - Drissa Makan Toure
Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, United States, USA
3 shared publications - Jon C. Schommer
Department of Pharmaceutical Care & Health Systems (PCHS), College of Pharmacy, University of Minnesota, 308 Harvard Street SE, Minneapolis, MN 55455, USA
3 shared publications - Olihe Okoro
Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota Duluth, 235 Life Science, Duluth, MN 55812, USA
3 shared publications - Taiwo Opeyemi Aremu
Department of Clinical and Social Pharmaceutical Sciences, College of Pharmacy, Touro University California, 1310 Club Dr., Vallejo, CA 94592, USA
3 shared publications
Latest Publications
- Open Access
Willingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willingness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State from 7 September to 16 September 2024, using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations using chi-square tests, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer–Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). Respondents were predominantly female (60.6%); the largest age groups were 25–34 (30.2%) and 35–44 (28.4%) years. Overall, 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p = 0.0028; trend p = 0.0002) and religion (p = 0.0403). In adjusted models, respondents aged 45–54 years (aOR 6.54; 95% CI: 1.73–24.79) and 55–64 years (aOR 4.97; 95% CI: 1.05–23.55) had higher odds of acceptance than those aged 18–24 years. Christian affiliation was associated with lower odds than Muslim affiliation (aOR 0.41; 95% CI: 0.20–0.83). Discrimination was acceptable (AUC 0.75; 95% CI: 0.69–0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
Open AccessWillingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willingness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State from 7 September to 16 September 2024, using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations using chi-square tests, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer–Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). Respondents were predominantly female (60.6%); the largest age groups were 25–34 (30.2%) and 35–44 (28.4%) years. Overall, 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p = 0.0028; trend p = 0.0002) and religion (p = 0.0403). In adjusted models, respondents aged 45–54 years (aOR 6.54; 95% CI: 1.73–24.79) and 55–64 years (aOR 4.97; 95% CI: 1.05–23.55) had higher odds of acceptance than those aged 18–24 years. Christian affiliation was associated with lower odds than Muslim affiliation (aOR 0.41; 95% CI: 0.20–0.83). Discrimination was acceptable (AUC 0.75; 95% CI: 0.69–0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- Open Access
- 24 April 2026
- Published by MDPI AG in Preprints.org
Willingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willing-ness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations with chi-square, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer-Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p=0.0028; trend p=0.0002) and religion (p=0.0403). In adjusted models, respondents aged 45-54 years (AOR 6.54; 95% CI 1.73-24.79) and 55-64 years (AOR 4.97; 95% CI 1.05-23.55) had higher odds of acceptance than those aged 18-24 years. Christian affiliation was associated with lower odds than Muslim affiliation (AOR 0.41; 95% CI 0.20-0.83). Discrimination was acceptable (AUC 0.75; 95% CI 0.69-0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- 24 April 2026
- Published by MDPI AG in Preprints.org
Open AccessWillingness to Accept a Locally Manufactured COVID-19 Vaccine in Lagos, Nigeria: A Cross-Sectional Survey and Demographic Predictors
Background: Local vaccine manufacturing is being pursued across Africa to improve pandemic preparedness and reduce reliance on imports. In Nigeria, where COVID-19 vaccines were largely imported, willingness to accept locally produced vaccines is important for sustainable domestic production. The objective of this study was to estimate willing-ness to accept a locally manufactured COVID-19 vaccine among adults in Lagos, Nigeria, and to identify demographic predictors. Methods: We conducted a cross-sectional survey of adults in Lagos State using a questionnaire administered in four open-air markets. The primary outcome was willingness to accept a COVID-19 vaccine manufactured in Nigeria (yes/no). We summarized respondent characteristics, tested bivariate associations with chi-square, and estimated adjusted odds ratios (AORs) using multivariable logistic regression. Model calibration and discrimination were assessed using Hosmer-Lemeshow testing and the area under the ROC curve (AUC). Results: Of 388 consenting respondents, 335 provided complete data (86.3%). 75.8% reported willingness to accept a Nigerian-made COVID-19 vaccine. Willingness differed by age group (p=0.0028; trend p=0.0002) and religion (p=0.0403). In adjusted models, respondents aged 45-54 years (AOR 6.54; 95% CI 1.73-24.79) and 55-64 years (AOR 4.97; 95% CI 1.05-23.55) had higher odds of acceptance than those aged 18-24 years. Christian affiliation was associated with lower odds than Muslim affiliation (AOR 0.41; 95% CI 0.20-0.83). Discrimination was acceptable (AUC 0.75; 95% CI 0.69-0.80). Conclusions: Most respondents were willing to accept a Nigerian-made COVID-19 vaccine, suggesting demand-side readiness. Confidence-building strategies tailored to younger adults and implemented with faith-based and community institutions may support uptake of locally produced vaccines.
- Open Access
- 11 March 2026
- Published by MDPI AG in Preprints.org
Building COVID-19 Vaccine Manufacturing Capacity in Nigeria: A Qualitative Needs Assessment of Barriers and Resource Requirements
Background: During the COVID-19 pandemic, Nigeria relied largely on imported vaccines, underscoring vulnerabilities in supply chains and the absence of domestic vaccine manufacturing. Understanding supply-related barriers and the resources required for local vaccine production is critical for future pandemic preparedness and population health outcome. The objective of the study was to identify stakeholder-perceived barriers to COVID‑19 vaccine manufacturing in Nigeria and to describe the resources and enabling conditions required for local production. Methods: We conducted a qualitative needs assessment using semi-structured interviews with senior personnel from Nigerian pharmaceutical manufacturing firms and regulatory agencies. Participants were recruited purposively and consecutively. Interviews (30-60 minutes) were conducted via Zoom, audio-recorded with consent, transcribed, and analyzed using inductive thematic analysis following established six-phase procedures. Reporting adheres to the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six participants (two regulators and four pharmaceutical executives) identified three interrelated barrier to domestic COVID-19 vaccine production: (1) technical and knowledge gaps (loss of hands-on expertise, absence of operational vaccine manufacturing facilities, limited technology transfer), (2) financial and infrastructure barriers (high cost of capital, serial taxation, unreliable electricity and logistics constraints), and (3) systemic and institutional barriers (inconsistent political commitment, policy discontinuity, regulatory capacity gaps, and concerns about public confidence). To enable local production, participants emphasized coordinated investment in workforce development, technology-transfer partnerships, modern utilities and cold chain systems, access to specialized equipment and high-quality inputs, and predictable policy, financing, and regulatory environments. Conclusions: Participants perceived Nigeria’s current capacity as insufficient for COVID-19 vaccine manufacturing but identified actionable levers, particularly human capital development, infra-structure strengthening, and regulatory and financing reforms, to enable sustainable local production. These findings provide a practical roadmap for policymakers, regulators, and industry leaders seeking to strengthen Nigeria’s biomanufacturing and long-term pan-demic preparedness.
- 11 March 2026
- Published by MDPI AG in Preprints.org
Open AccessBuilding COVID-19 Vaccine Manufacturing Capacity in Nigeria: A Qualitative Needs Assessment of Barriers and Resource Requirements
Background: During the COVID-19 pandemic, Nigeria relied largely on imported vaccines, underscoring vulnerabilities in supply chains and the absence of domestic vaccine manufacturing. Understanding supply-related barriers and the resources required for local vaccine production is critical for future pandemic preparedness and population health outcome. The objective of the study was to identify stakeholder-perceived barriers to COVID‑19 vaccine manufacturing in Nigeria and to describe the resources and enabling conditions required for local production. Methods: We conducted a qualitative needs assessment using semi-structured interviews with senior personnel from Nigerian pharmaceutical manufacturing firms and regulatory agencies. Participants were recruited purposively and consecutively. Interviews (30-60 minutes) were conducted via Zoom, audio-recorded with consent, transcribed, and analyzed using inductive thematic analysis following established six-phase procedures. Reporting adheres to the Consolidated Criteria for Reporting Qualitative Research (COREQ). Results: Six participants (two regulators and four pharmaceutical executives) identified three interrelated barrier to domestic COVID-19 vaccine production: (1) technical and knowledge gaps (loss of hands-on expertise, absence of operational vaccine manufacturing facilities, limited technology transfer), (2) financial and infrastructure barriers (high cost of capital, serial taxation, unreliable electricity and logistics constraints), and (3) systemic and institutional barriers (inconsistent political commitment, policy discontinuity, regulatory capacity gaps, and concerns about public confidence). To enable local production, participants emphasized coordinated investment in workforce development, technology-transfer partnerships, modern utilities and cold chain systems, access to specialized equipment and high-quality inputs, and predictable policy, financing, and regulatory environments. Conclusions: Participants perceived Nigeria’s current capacity as insufficient for COVID-19 vaccine manufacturing but identified actionable levers, particularly human capital development, infra-structure strengthening, and regulatory and financing reforms, to enable sustainable local production. These findings provide a practical roadmap for policymakers, regulators, and industry leaders seeking to strengthen Nigeria’s biomanufacturing and long-term pan-demic preparedness.